Bioengineer

JANUARY 16, 2024

This mutation hinders the drug’s binding to the mutant EGFR protein. Osimertinib, however, can covalently bind to the T790M and cysteine-797 (C797) residue at the protein’s ATP binding site, overcoming resistance mechanisms. Real-world cohorts report a prevalence of C797 mutations between 11% and 29%.

Genome 119

Genome Genomics Protein In-Vitro 119

Roots Analysis

AUGUST 12, 2024

These diagnostic solutions are essential for detecting and monitoring diseases, identifying genetic abnormalities, and guiding personalized treatment plans. Molecular diagnostic solutions are pivotal across various medical fields, including oncological disorders, infectious diseases, genetic testing, and personalized medicine.

Genetics 40

Genetics Gene Expression RNA DNA 40

Worldwide Clinical Trials

AUGUST 14, 2024

Historically, these indications have challenged the one-size-fits-all treatment approach due to patient variability, such as genetic differences in drug metabolism and underlying health conditions. This resistance may occur due to genetic mutations, epigenetic changes, or a tumor’s microenvironment.

Genetics 130

Genetics Protein Gene Genotype 130

Roots Analysis

AUGUST 31, 2023

Recent advances in DNA sequencing technologies have led to significant developments in healthcare-focused research on precision medicine and diagnostics. Nutritional DNA testing helps in identifying foods that might lead to allergies or intolerance in an individual.

Genome 40

Genome Genomics Genetics Gene 40

Drug Discovery World

JULY 15, 2022

The remaining 8% of the genome was often referred to as the dark matter of the genome or sometimes even ‘Junk DNA’ 2. The sequencing technology relied on could only yield sequences of relatively short DNA fragments, so the assembly of sequences from highly repetitive regions was a huge challenge.

Genome 52

Genome Genomics DNA Containment 52